Impact of the Leu7Pro polymorphism of preproNPY on diurnal NPY and hormone secretion in type 2 diabetes.
Neuropeptide Y (NPY) is a sympathetic neurotransmitter that plays a role in e.g. circulation, hormone release and angiogenesis. Earlier studies have shown that the Leucine 7 to Proline 7 (Leu7Pro) polymorphism of preproNPY is associated with increased risk for vascular complications in type 2 diabetes. The mechanism for this maybe altered transmitter and hormone levels or altered cardiovascular functions, which have been observed in healthy subjects having the Leu7Pro polymorphism. The current study was undertaken to explore if the Leu7Pro polymorphism has an impact on these functions in subjects with type 2 diabetes. Diurnal measurements were performed for Finnish Caucasian type 2 diabetes patients of two preproNPY genotypes (matched by sex, age, BMI, duration of diabetes and HbA1c) in resting position to prevent sympathetic stimulation. Standard meals were offered during the 24-hour study period. Nine subjects with the Leu7Pro polymorphism and ten subjects without this polymorphism were studied. Plasma concentrations of NPY, glucose, insulin, cortisol, prolactin and leptin were measured by taking blood samples at 20 time points (from 8 a.m. to 8 a.m.). Heart rate and blood pressure were measured at the same time points. The results show that NPY concentrations were similar in both preproNPY genotypes. Glucose, insulin, cortisol and leptin concentrations as well as heart rate and blood pressure were also similar. However, a significant difference between genotypes was found in the association of NPY concentrations with cortisol concentrations (p for difference=0.002). Also a statistically significant negative association of plasma NPY levels with plasma glucose levels was found in both genotypes. Since no impact of preproNPY genotype on mean NPY or hormone levels were detected in subjects with type 2 diabetes, the mechanisms for the increased risk for diabetic complications in the subjects with the Leu7Pro polymorphism need to be further explored.
Jaakkola
U
U
Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland. ulriikka.jaakkola@utu.fi
Koulu
M
M
Karvonen
M K
MK
Seppälä
H
H
Pesonen
U
U
Vahlberg
T
T
Kallio
J
J
D000368:Aged; D019943:Amino Acid Substitution / Q000235:genetics; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D020738:Leptin / Q000097:blood; D007930:Leucine / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D011110:Polymorphism, Genetic; D011392:Proline / Q000235:genetics; D011498:Protein Precursors / Q000235:genetics*
D001786:Blood Glucose; D020738:Leptin; D009478:Neuropeptide Y; D011498:Protein Precursors; C042084:preproneuropeptide Y; D011392:Proline; D007930:Leucine; D006854:Hydrocortisone